Targeted Oncology5h
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
Oncology Nurse Advisor5h
Imlunestrant Bests Standard Care in Certain Patients With ER+, HER2- Breast Cancer
The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...
oncnursingnews8h
T-DXd Companion Diagnostic in HER2-Ultralow Metastatic Breast Cancer Gains FDA Approval
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
emjreviews.com10h
Ultrafast MRI Matches Standard MRI for Breast Cancer Classification
Study finds that ultrafast MRI-based radiomics model performs just as well as standard MRI in classifying breast cancer ...
RAD51 biomarker could complement next-generation sequencing in personalizing prostate cancer treatment
Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...